



ACT
Government

**Canberra Health
Services**

Canberra Region Cancer Centre

Research Highlights 2023

Date: 5 February 2024



Contents

Immunology: Research Highlights 2023	2
Haematology and Laboratory Haematology: Research Highlights 2023	4
Medical Oncology: Research Highlights 2023.....	16
Radiation Oncology: Research Highlights 2023	22
Palliative Care: Research Highlights 2023.....	26

Names in bold indicate researcher employed at the Canberra Region Cancer Centre

Immunology and Immunopathology: Research Highlights 2023

Publications 2023

1. Lee W-I, Lam L, Bacchi S, Jiang M, Inglis JM, Smith W and Hissaria P (2024) 'Antibiotic prophylaxis in immunosuppressed patients - Missed opportunities from trimethoprim-sulfamethoxazole allergy label', *The World Allergy Organization journal*, 17(1):100856, doi:10.1016/j.waojou.2023.100856.
2. Hossain ME, Kennedy KJ, Wilson HL, Spratt D, Koehler A, Gasser RB, Šlapeta J, Hawkins CA, Bandi HP and Senanayake SN (2023) 'Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid', *Emerging infectious diseases*, 29(9):1900–1903, doi:10.3201/eid2909.230351.

Conference oral presentations 2023

1. **Randall, KL.** DOCK8 deficiency and other actin pathway defects. Invited presentation, Annual Scientific Meeting of the Australian Society of Infectious Diseases, Adelaide, April 2023
2. **Randall KL.** Investigating T follicular cell numbers and neuritin levels in patients with food allergy. Invited presentation, Annual Scientific Meeting of the Australasian Society of Clinical Immunology and Allergy, Sydney, Sept 2023

Research grants 2023

Project Title: Improving outcomes for patients with allergy and immunodeficiency in the ACT using a phenomics and genomics-based approach.
Funding body: ACT Health Research Innovation Fund (RIF) Fellowship
Investigator: Katrina Randall
Amount: \$200K

Project Title: 2023/MRF2025693: Improving genetic diagnosis of autoimmune and autoinflammatory disease through an integrated multi-omics approach
Funding body: MRFF
Investigator: CIA Simon Jiang, CIE Randall
Amount: \$2,950,844.17

Research awards 2023

- Associate Professor Katrina Randall awarded with the competitive ACT Health Research Innovation Fund (RIF) Fellowship (see also under grants)

New research projects 2023

Local Reference	Local Site Principal Investigator	Project Title	Study Phase/Type	ACT Health/CHS Area/Unit	Student Project (Y/N)	Sponsor Type
2023.ETH.00027	A/Professor Katrina Randall	Canberra Clinical Phenomics	Clinical Research	Immunology	No	Collaborative Group
2023.STE.00167	A/Professor Katrina Randall	Investigation and Research of Patients with Immune Dysfunction	Clinical Research	Immunology	No	Collaborative group

Open clinical trials

Trial short reference	PI	Title	Disease	Sponsor Type
OCEAN	Dr Wei-I Lee	Efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA)	Eosinophilic Granulomatosis with Polyangiitis (EGPA)	Pharmaceutical sponsor
DESTINY	Dr Wei-I Lee	Depemokimab in participants with hypereosinophilic syndrome, efficacy, and safety trial	Hypereosinophilic Syndrome	Pharmaceutical sponsor

Haematology and Laboratory Haematology: Research Highlights 2023

Publications 2023

1. Anderson MA, Bennett R, Badoux X, Best G, Chia N, Cochrane T, Cull G, Crassini K, Harrup R, Jackson S, Kuss B, Lasica M, Lew TE, Marlton P, Opat S, Palfreyman E, **Polizzotto MN**, Ratnasingam S, Seymour JF, Soosapilla A, **Talaulikar D**, Tam CS, Weinkove R, Wight J and Mulligan SP (2023) 'Chronic lymphocytic leukaemia Australasian consensus practice statement.', *Internal medicine journal*, 53(9):1678–1691, doi:10.1111/imj.16207.
2. Arulogun SO, Brian D, Goradia H, Cooney A, Menne T, Koo R, O'Neill AT, Vos JMI, Pratt G, Turner D, Marshall K, Manos K, Anderson C, Gavriatopoulou M, Kyriakou C, Kersten MJ, Minnema MC, Koutoumanou E, El-Sharkawi D, Linton K, **Talaulikar D**, McCarthy H, Bishton M, Follows G, Wechalekar A and D'Sa SP (2023) 'Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.', *American Journal of Hematology*, 98(5):750–759, doi:10.1002/ajh.26895.
3. Baggio D, Wellard C, Chung E, **Talaulikar D**, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA, Balendra J, Barraclough A, Berkahn L, Bosco A, Carradice D, Chuah H, Coyle L, Crassini K, Kenealy M, Ku M, Leung T, Manos K, Morgan S, Mutsando H, Narayana M, Palfreymen E, Prince M, Ratnasingam S, Simpson J, Trotman J, Viala N and Wight J (2022) 'Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry', *Leukemia & Lymphoma*, 64(3):621–627, doi:10.1080/10428194.2022.2157676.
4. Barnes GD, Ageno W, Castellucci LA, Chiasakul T, **Eslick R**, Ferreiro JL, Gailani D, Gorog DA, Lip GH, Raffini L, Rezende SM, Weitz JI and Cuker A (2023) 'Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on the Control of Anticoagulation', *Journal of thrombosis and haemostasis : JTH*, 21(5):1381–1384, doi:10.1016/j.jtha.2023.02.008.
5. Byonanebye DM, **Polizzotto MN**, Parkes-Ratanshi R, Musaazi J, Petoumenos K and Castelnuovo B (2023) 'Prevalence and incidence of hypertension in a heavily treatment-experienced cohort of people living with HIV in Uganda', *PLoS one*, 18(2):e0282001–e0282001, doi:10.1371/journal.pone.0282001.
6. Chai KL, Wong J, Weinkove R, Keegan A, **Crispin P**, Stanworth S, Morrissey CO, Wood EM and McQuilten ZK (2023) 'Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis', *Blood advances*, 7(1):20–31, doi:10.1182/bloodadvances.2022008073.
7. **Choi PY-I**, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Merriman E, Yong ASM, Simpson J, Gardiner E, Cherbuin N, Curnow J, Pepperell D and Bird R (2023) 'Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to pre-pandemic patients', *Research and practice in thrombosis and haemostasis*, 7(1):100009, doi:10.1016/j.rpth.2022.100009.
8. **Choi P**, Merriman E, Bennett A, Enjeti A, Tan CW, Goncalves I, Hsu D and Bird R (2023) 'Updated treatment options for immune thrombocytopenia', *Internal Medicine Journal*, doi:10.1111/imj.16246.

9. Coombes C, Horikawa K, Jain S, Jiang S, Lim JH, Saxena K, Shadbolt B, Smyth L, Tobin J and **Talaulikar D** (2023) 'Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.', *Pathology*, 55(1):104–112, doi:10.1016/j.pathol.2022.07.017.
10. Coupland LA, Rabbolini DJ, Schoenecker JG, **Crispin PJ**, Miller JJ, Ghent T, Medcalf RL and Aneman AE (2023) 'Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study', *Critical care (London, England)*, 27(1):55, doi:10.1186/s13054-023-04329-5.
11. Dharan NJ, Sasson SC, Ahlenstiel G, Andersen CR, Bloch M, Buckland G, Hamad N, Han WM, Kelleher AD, Long G V, Matthews G V, Mina MM, Papot E, Petoumenos K, Swaminathan S, Withers B, Yun J, **Polizzotto MN** and Group CS (2023) 'Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia', *PLoS one*, 18(11):e0289907–e0289907, doi:10.1371/journal.pone.0289907.
12. **Di Ciaccio PR, Polizzotto MN**, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson A-M, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW and Hamad N (2024) 'The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma', *Blood*, 143(2):152–165, doi:10.1182/blood.2023021348.
13. **Di Ciaccio PR**, Van Leeuwen MT, Amin J, Vajdic CM, McGregor S, Poynten IM, Templeton DJ, Law M, Grulich AE, **Polizzotto MN** and Jin F (2023) 'Second Primary Cancers in People With HIV/AIDS: A National Data Linkage Study of Incidence and Risk Factors', *Journal of acquired immune deficiency syndromes* (1999), 93(1):25–33, doi:10.1097/QAI.0000000000003172.
14. **Di Ciaccio PR**, Mills G, Shipton MJ, Campbell B, Gregory G, Langfield J, Greenwood M, McKeague S, Shanavas M, **Eslick R**, Kidson-Gerber G, Smallbone P, Tang C, Morris K, Bilmon I, Yannakou CK, Badoux X, Berkahn L, Farina S, Mason KD, Motum P, Goss K and Hamad N (2023) 'The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance', *British Journal of Haematology*, 201(5):887–896, doi:10.1111/bjh.18727.
15. D'Sa S, Matous J V, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, **Talaulikar D**, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP and Kastritis E (2023) 'Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.', *Seminars in hematatology*, 60(2):80–89, doi:10.1053/j.seminhematol.2023.03.003.
16. Goh Z, **Latimer M**, Lewis KL, Cheah CY, **Ciaccio P Di**, Cushion T, Hawkes EA, Harrop S, Ku M, Campbell A, Hamad N, Wood EM, Chung E, Chen P-Y and Cochrane T (2023) 'Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study', *Clinical Lymphoma Myeloma and Leukemia*, 23(5):370–378, doi:10.1016/j.clml.2023.01.014.
17. Joel CT, Burgess M and **Crispin P** (2023) 'Costs and consequences of over-investigation of minor transfusion reactions', *Internal Medicine Journal*, doi:10.1111/imj.16183.
18. Kuo NI-H, Garcia F, Sönnernborg A, Böhm M, Kaiser R, Zazzi M, Polizzotto M, Jorm L and Barbieri S (2023) 'Generating synthetic clinical data that capture class imbalanced

distributions with generative adversarial networks: Example using antiretroviral therapy for HIV', *Journal of Biomedical Informatics*, 144:104436, doi:10.1016/j.jbi.2023.104436.

19. Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC and Cheah CY (2023) 'High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.', *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 41(35):5376–5387, doi:10.1200/JCO.23.00365.
20. Li, E., Bryant, C.E., Jones, E., King, T., **Talaulikar, D.**, Ng, J., et al. (2023). P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy. *Clinical Lymphoma Myeloma and Leukemia*. 23 (196)
21. Liam CCK, Tiao JY-H, Yap YY, Lee YL, Sathar J, McRae S, Davis A, Curnow J, Bird R, **Choi P**, Angchaisuksiri P, Tien SL, Lam JCM, Oh D, Kim JS, Yoon S-S, Wong RS-M, Lauren C, Merriman EG, Enjeti A, Smith M and Baker RI (2023) 'Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)', *Blood research*, 58(1):36–41, doi:10.5045/br.2023.2022133.
22. Lim KJC, Di **Ciaccio P**, **Polizzotto MN**, Milliken S, Cochrane T, Goh Z, Shaw B, Perry E, Gilbertson M, Kermode W, Cheah CY, **Latimer M**, Hamad N and Ku M (2023) 'Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance', *British Journal of Haematology*, 201(5):865–873, doi:10.1111/bjh.18704.
23. Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, **Latimer M**, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ and Wei AH (2023) 'Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG', *Blood*, 142(23):1960–1971, doi:10.1182/blood.2023020301.
24. Lurain K, **Polizzotto MN**, Krug LT, Shoemaker G, Singh A, Jensen SMR, Wyvill KM, Ramaswami R, Uldrick TS, Yarchoan R and Sereti I (2023) 'Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration', *AIDS (London, England)*, 37(11):1693–1703, doi:10.1097/QAD.0000000000003627.
25. Mills GS, Chadwick V, Tang C, Perram J, Anderson MA, Anazodo A, Kidson-Gerber G, Shand A, Lavee O, Withers B, Milliken S, **Di Ciaccio PR** and Hamad N (2023) 'Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility', *The Lancet Haematology*, 10(6): e458–e467, doi:10.1016/s2352-3026(23)00059-5.
26. Mills GS, Di **Ciaccio PR**, Tang C, Chadwick V, Mason KD, Campbell BA, Shipton MJ, Shanavas M, Morris KL, Greenwood M, Langfield J, Kidson-Gerber G, **Eslick R**, Badoux X, Yannakou CK, Gangatharan SA, Bilmon I and Hamad N (2023) 'Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study', *Leukemia & Lymphoma*, 64(2):319–328, doi:10.1080/10428194.2022.2148376.
27. Minson A, Hamad N, **Di Ciaccio P**, **Talaulikar D**, Ku M, Ratnasingam S, Cheah C, Yannakou CK, Bishton M, Ng ZY, Agrawal S, McQuillan A, Johnston A, Choong E, Wong K, McQuillan J, Beekman A, Hawkes E and Dickinson M (2023) 'Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.', *British Journal of Haematology*, doi:10.1111/bjh.19179.

28. Moore M, Northey JM, **Crispin P**, Semple S and Toohey K (2023) 'Effects of Exercise Rehabilitation on Physical Function in Adults With Hematological Cancer Receiving Active Treatment: A Systematic Review and Meta-Analysis', *Seminars in Oncology Nursing*, 39(6):151504, doi:10.1016/j.soncn.2023.151504.
29. Murray DD, Grund B, MacPherson CR, Ekenberg C, Zucco AG, Reekie J, Dominguez-Dominguez L, Leung P, Fusco D, Gras J, Gerstoft J, Helleberg M, Borges ÁH, **Polizzotto MN**, Lundgren JD (2023) 'Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV', *AIDS (London, England)*, 37(3):379–387, doi:10.1097/QAD.0000000000003427.
30. Ng JY, Joshi M and **Choi P** (2023) 'Frequency and outcomes of obinutuzumab-induced thrombocytopenia', *British Journal of Haematology*, 203(4):668–672, doi:10.1111/bjh.19147.
31. Ng JY, Warwick L, Craft P, Austen L, Ashford B, Gorddard N, Ballinger ML, Thomas DM, Blombery P, Tucker K and **Polizzotto MN** (2023) 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', *British Journal of Haematology*, 203(3):481–484, doi:10.1111/bjh.19059.
32. Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, **Talaulikar D**, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barracough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK and Hawkes EA (2023) 'Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry', *European Journal of Haematology*, 110(4):386–395, doi:10.1111/ejh.13915.
33. Ningtyas DC, Leitner F, Sohail H, Thong YL, Hicks SM, Ali SA, Drew ME, Javed K, Lee J, Kenangalem E, Poespoprodjo JR, Anstey NM, Rug M, **Choi PY**, Kho S, Gardiner EE and McMorran BJ (2023) 'Platelets mediate the clearance of senescent red blood cells by forming pro-phagocytic platelet-cell complexes.', *Blood Journal*, doi:10.1182/blood.2023021611.
34. Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson A-M, Diamond P, **Latimer M**, Irving I, Blyth E, Cheah C, Cole T (2023) 'Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell'. *Internal Medicine Journal*, 53(1), pp.119-125. doi.org/10.1111/imj.15978
35. **Polizzotto MN** (2023) 'Deconstructing the liquid architecture of human herpesvirus 8 diseases', *British journal of haematology*, 200(4):401–403, doi:10.1111/bjh.18546.
36. Reilly CS, Borges ÁH, Baker J V, Safo SE, Sharma S, **Polizzotto MN**, Pankow JS, Hu X, Sherman BT, Babiker AG, Lundgren JD and Lane HC (2023) 'Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV', *The Journal of infectious diseases*, 227(8):951–960, doi:10.1093/infdis/jiac496.
37. Safo SE, Haine L, Baker J, Reilly C, Duprez D, Neaton JD, Jain MK, Arenas-Pinto A, **Polizzotto M**, Staub T (2023) 'Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort', *Journal of the American Heart Association*, 12(13):e027273–e027273, doi:10.1161/JAHA.122.027273.
38. Samaraweera SE, Geukens T, Casolari DA, Nguyen T, Sun C, Bailey S, Moore S, Feng J, Schreiber AW, Parker WT, Brown AL, Butcher C, Bardy PG, Osborn M, Scott HS, **Talaulikar D**,

- Grove CS, Hahn CN, D'Andrea RJ and Ross DM (2023) 'Novel modes of MPL activation in triple-negative myeloproliferative neoplasms.', *Pathology*, 55(1):77–85, doi:10.1016/j.pathol.2022.05.015.
39. Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS, Hampton HR, Vaughan L, Rutherford K, Kakadia PM, Lee HM, Johansson EM V, Failes TW, Arndt GM, Koval J, Lindeman R, Warburton P, Rodriguez-Meira A, Mead AJ, Unnikrishnan A, Davidson S, **Polizzotto MN**, Hertzberg M, Papaemmanuil E, Bohlander SK, Faridani OR, Jolly CJ, Zanini F and Pimanda JE (2023) 'Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy', *Blood*, 141(11):1316–1321, doi:10.1182/blood.2022018602.
 40. Sim S, Kalff A, Tuch G, Mollee P, Ho PJ, Harrison S, Gibbs S, Prince HM, Spencer A, Joshua D, Lee C, Ling S, Murphy N, Szabo F, Szer J, Weber N, Ward C, **Talaulikar D**, Zannettino A and Quach H (2023) 'The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.', *Internal medicine journal*, 53(5):819–824, doi:10.1111/imj.16049.
 41. Stadler E, Burgess MT, Schlub TE, Khan SR, Chai KL, McQuilten ZK, Wood EM, **Polizzotto MN**, Kent SJ, Cromer D, Davenport MP and Khouri DS (2023) 'Monoclonal antibody levels and protection from COVID-19', *Nature communications*, 14(1):4545, doi:10.1038/s41467-023-40204-1.
 42. Stadler E, Chai KL, Schlub TE, Cromer D, Khan SR, **Polizzotto MN**, Kent SJ, Beecher C, White H, Turner T, Skoetz N, Estcourt L, McQuilten ZK, Wood EM, Khouri DS and Davenport MP (2023) 'Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis', *The Lancet Microbe*, 4(11): e883–e892, doi:10.1016/s2666-5247(23)00194-5.
 43. **Talaulikar D**, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson BM, Trotman J, Harrison SJ and Tam CS (2023) 'Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.', *Internal medicine journal*, 53(4):599–609, doi:10.1111/imj.15980.
 44. **Talaulikar D**, Tomowiak C, Toussaint E, Morel P, Kapoor P, Castillo JJ, Delmer A and Durot E (2023) 'Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.', *Hematology/oncology clinics of North America*, 37(4):787–799, doi:10.1016/j.hoc.2023.04.009.
 45. Tan KP, **Talaulikar D** and Scholz B (2023) 'Factors of emotional distress in lymphoma: A systematic review.', *Cancer medicine*, 12(13):14646–14662, doi:10.1002/cam4.6069.
 46. Teh BW, Reynolds G, Slavin MA, Cooley L, Roberts M, Liu E, Thursky K, **Talaulikar D**, Mollee P, Szabo F, Ward C, Chan H, Prince HM and Harrison SJ (2023) 'Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.', *Internal medicine journal*, 53(8):1469–1477, doi:10.1111/imj.16100.
 47. Tran HA, Deng L, Wood N, **Choi P**, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Gold M, Hissaria P, Melody S, Chunilal S SD, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E and Chen VM (2023) 'The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study', *The Lancet regional health. Western Pacific*, 40:100894, doi:10.1016/j.lanwpc.2023.100894.
 48. Webb F, Morey A, Mahler-Hinder C, Georgousopoulou E, Koo R, **Pati N** and **Talaulikar D** (2023) 'Comprehensive FISH testing using FFPE tissue microarray of primary lymph node

- tissue identifies secondary cytogenetic abnormalities in Mantle Cell Lymphoma.' *Cancer genetics*, 274–275:75–83, doi:10.1016/j.cancergen.2023.04.002.
49. Yip D, Soma A, Pati N, Spencer W, Hua B and Jagilly R (2023) 'Building Capability and Capacity: The Establishment of an Oncology Unit in the Solomon Islands', *JCO global oncology*, 9: e2200325–e2200325, doi:10.1200/GO.22.00325.
 50. Zucco AG, Bennedbæk M, Ekenberg C, Gabrielaite M, Leung P, Polizzotto MN, Kan V, Murray DD, Lundgren JD, MacPherson CR and group IS study (2023) 'Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohort', *AIDS (London, England)*, 37(11):1643–1650, doi:10.1097/QAD.0000000000003557.

Conference oral presentations 2023

Conference presentations and abstracts for Dipti Talaulikar

- Li, E, Bryant, C, Jones, E, King, T, **Talaulikar, D**, Ng, J, Bryant, A, Ridha, Z, Doo, NW, Ling, S and Ho, PJ, (2023). P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy. *Clinical Lymphoma Myeloma and Leukemia*, 23, p.S196.
- Opat, S., Tedeschi, A., Hu, B., Linton, K., Mckay, P., Leitch, S., Jin, J., Sun, M., Sobieraj-Teague, M., Zinzani, P.L. and Browett, P., 2023. P1084: Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (r/r) marginal zone lymphoma (mzl): final analysis of the magnolia (bgb-3111-214) trial. *HemaSphere*, 7(S3), p.e77003b0.
- Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., **Talaulikar, D.**, Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M.K. and Keane, C. (2023), Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. *Hematological Oncology*, 41: 278-279. https://doi.org/10.1002/hon.3164_191
- Binkley, M.S., Flerlage, J.E., Borchmann, P., Fuchs, M., Hartmann, S., Eich, H.T., Savage, K.J., Lo, A., Skinnider, B., Akhtar, S., Rauf, M.S., Maghfoor, I., Pinnix, C.C., Steiner, R., Milgrom, S.A., Vega, F., Alomari, M., Zhang, X., Collins, G., Advani, R.H., Metzger, M., Dickinson, M., Wirth, A., Tsang, R., Prica, A., Major, A., Smith, S., Hendrickson, P.G., Kelsey, C.R., Hopkins, D., McKay, P., Ng, A., Koenig, J., Constine, L.S., Casulo, C., Sakthivel, G., Baron, J., Plastaras, J.P., Roberts, K.B., Gao, S., Al Kendi, J., Al Rahbi, N., Balogh, A., Levis, M., Ricardi, U., Sridhar, A., Torka, P., Specht, L., De Silva, R., Shah, N., Pickard, K., Osborne, W., Blazin, L.J., Henry, M., Chang, I., Smith, C.M., Halperin, D., Miali, F., Brady, J., Mikhaeel, G., Brennan, B., Penn, A., Senchenko, M.A., Volchkov, E.V., Reeves, M., Hoppe, B., Terezakis, S., **Talaulikar, D.**, Della Pepa, R., Picardi, M., Kirova, Y., Fergusson, P., Northend, M., Shankar, A., Maurer, M.J., Natkunam, Y., Kelly, K.M., Eichenauer, D.A. and Hoppe, R.T. (2023), The prognostic impact of clinical factors and immunoarchitectural patterns for nodular lymphocyte-predominant Hodgkin Lymphoma: an international study by glow. *Hematological Oncology*, 41: 100-101. https://doi.org/10.1002/hon.3163_62
- **Talaulikar, D.**, Brysland, S. and Gardiner, E., 2023. P-446 Waldenström Macroglobulinaemia lymphoma patients have impaired platelet haemostatic function. *Clinical Lymphoma Myeloma and Leukemia*, 23, p.S286.

- **Talaulikar D.**, Gao L., Nguyen D., Mudiyanselage SB, Tang B., Zhao FL., (2023). Incidence, Prevalence, and Mortality of Waldenström Macroglobulinemia in Australia. The combined Annual Scientific Meeting of the Blood 2023.

Conference presentations and abstracts for Dipti Talaulikar

- **Eslick R.**, Australian and New Zealand College of Anaesthetists (ANZCA) Annual Scientific Meeting, Sydney. Invited speaker for the obstetric anaesthesia special interest group session. "Management of thrombocytopenia in pregnancy and delivery". May 2023.
- **Eslick R.**, Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Obstetric Medicine Update Course, virtual. Invited speaker. "Anaemia in pregnancy". May 2023.
- **Eslick R.**, International Society on Thrombosis and Haemostasis (ISTH) Congress, Montreal. Career development session "How to be an effective clinical educator in thrombosis and haemostasis". June 2023.
- **Eslick R.**, Disorders of Complement meeting, Melbourne. Invited speaker. "Complement-mediated TMAs in pregnancy". July 2023.
- **Eslick R.**, Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Annual Scientific Meeting, Adelaide. Invited speaker. "Diagnosis and management of immune thrombocytopenia in pregnancy", as well as member of panel discussion. October 2023.
- **Eslick R.**, The Annual Women's and Children's Health Update, HealthEd, multiple meetings (Brisbane, Sydney, Melbourne, Perth). Invited speaker. "Iron and pregnancy: important recent developments".
- **Eslick R.**, Early Life Nutrition Alliance, virtual Congress. Invited speaker. "Iron deficiency in pregnancy". November 2023.

Conference presentations and abstracts for Phillip Choi

- **Choi P.**, ITP Australia Patient Conference Brisbane "Clinical trials in ITP" March 2023
- **Choi P.**, ISTH-SSC Montreal "New guidance on HIT treatment" June 2023
- **Choi P.**, Novartis GET meeting Sydney "Treating ITP in 2023" July 2023
- **Choi P.**, Sobi A RARE afternoon of complements and platelets meeting Melbourne "Advances in ITP" November 2023
- **Choi P.**, THANZ Workshop Melbourne "Building bridges between platelets and researchers" November 2023
- **Choi P.**, BLOOD conference "Using AI to decipher thrombocytopenia" November 2023
- **Choi P.** Highlights of EHA23 and ICML17, "The Limbic", July 2023

Conference presentations and abstracts for Phillip Crispin

- Wood EM, Chai KL, Reynolds J, Griffiths J, Beaton B, Callum J, Crassin KR, **Crispin PJ**, Eise N, Fanning L, Gilbertson M, Grigg AP, Hawkes EA, Morrissey CO, Mulligan SP, Opat SS, Paterson DL, Petrie D, Roberts JA, Ryan EG, Spencer A, Stanworth SJ, Phuong Thao LT, Trotman J, Waters J, Weinkove R and McQuilten ZK. Optimizing immunoglobulin replacement therapy for patients with B-cell malignancies and hypogammaglobulinaemia. The investigator-initiated,

international, randomized phase II/III RATIONAL platform trial, and the RATIONALISE (STOP IgRT) domain, American Society of Hematology Meeting December 2023.

- **Crispin P.** Transfusion Associated Graft Versus Host Disease. Blood 2023 Meeting Melbourne 2023. *Invited Speaker*
- Coupland L, Rabboni D, **Crispin P**, Aneman A. Fibrinolysis shutdown and kinetics of normalisation in a critically unwell patient: a case report from the VETtiPAT clinical trialists. Blood 2023 Meeting Melbourne 2023.
- Carillo de Albornoz S, Higgins A, Petrie D, Irving A, Fanning L, Wood E, van Tonder T, Wellard C, Reynolds J, Weinkove R, **Crispin P**, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Trotman J, Pullon H, Weston H, Morrissey O, McQuilten Z. Economic evaluation of prophylactic immunoglobulin versus prophylactic antibiotics in haematological malignancies: preliminary results from the RATIONAL feasibility trial. Blood 2023 Meeting Melbourne 2023.
- Brysland S, **Crispin P**, Talaulikar D, Gardiner E. Waldenstrom macroglobulinaemia lymphoma patients have impaired global haemostatic function. Blood 2023 Meeting Melbourne 2023.
- Joel C, Burgess M, **Crispin P**. Consequences of over-investigation of minor transfusion reactions, CHARM 2023
- Joel C, Burgess M, **Crispin P**. Appropriateness of transfusion reaction investigations. International Society of Blood Transfusion Gothenburg June 2023
- **Crispin P**, Grove K, Lamond D. O RhD Negative Demand in a Regional Aero Retrieval Service. International Society of Blood Transfusion Gothenburg June 2023

Conference presentations and abstracts for Pietro Di Ciaccio

- **Di Ciaccio P.**, Highlights of EHA23 and ICML17, The Limbic, July 2023

Conference presentations and abstracts for Maansi Joshi

- **Joshi M.**, ANZSPM palliative care conference: topic: An update on CAR-T cell therapy

Conference presentations and abstracts for Jun Ng

- **Ng JW, Ooi M, Bennett S, Rady K, Choi P, Lee, WI, Cook M, Randall K, Pati N**, Acquired angioedema associated with lymphoproliferative disorders: a case series; Abstract in The European Hematology Association 2023 Hybrid Congress

Conference poster presentations 2023

1. **Talaulikar D**, Pandey A, Venkataraman S, Vedantham D, Man SM (2023) 'A High-Throughput Screen Identifies New Drugs for the Treatment of Lymphoma. *Blood*: 142 (Supplement 1): 1437. 65th Annual Meeting of American Society of Hematology. December 9-12, 2023 San Diego, CA. 605: doi: <https://doi.org/10.1182/blood-2023-179016>.
2. **Lee W-I**, Lam L, Bacchi S, Jiang M, Inglis JM, Smith W and Hissaria P (2023) 'Antibiotic prophylaxis in immunosuppressed patients - Missed opportunities from trimethoprim-

sulfamethoxazole allergy label', *The World Allergy Organization journal*, 17(1):100856,doi:10.1016/j.waojou.2023.100856.

3. Tobin JW, Chowdhury R, Salvaris R, Griffin A, Chikatamarla V, Goh A, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Steinepreis E, Chen Y, Black H, Broadby G, Li L, Gutta N, Morris KL, Cochrane T, Trotman J, **Talaulikar D**, Shortt J, Hodges G, Cheah CY, Barraclough A, Manos K, Johnston AM, Royle J, Mondello P, Ansell S, Hapgood G (2023); The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival. *Blood* ; 142 (Supplement 1): 1671. doi: <https://doi.org/10.1182/blood-2023-185879> 623
4. **D'Souza M.** (2023) Pembrolizumab, PML and Hodgkins Lymphoma; An interesting Triad'. *Blood* 2023;
5. Mann R, Whiting P, **Di Ciaccio P.** "Comparing the Efficiency of Smart Blood Fridge Systems and Traditional Practices in Transfusion Metrics" *Blood*, HSANZ, Melbourne 2023
6. **Ng JY, Lenton D, Kerridge I, Wong C.** A case report of quinine-induced thrombotic microangiopathy successfully treated with eculizumab. ISTH 2023
7. **Ng JY, Joshi M, Choi P.** Obinutuzumab-induced thrombocytopenia: an under-recognized immunotherapy related thrombocytopenia. ISTH 2023
8. **Ng, JY, Ooi M, Bennett S, Rady K, Choi P, Lee WI, Cook M, Randall K, Pati N.** Acquired angioedema associated with lymphoproliferative disorders: a case series.Poster presentation at Blood, HSANZ, Melbourne 2023
9. **Ng JY, Joshi M, Choi P.** Frequency and Outcomes of Obinutuzumab-Induced Thrombocytopenia. Poster presentation in ASH 2023
10. **Ng JY, Fernando S, Phipp L, Wong C, Fogo K, Crameri D, Lenton D,** Therapeutic apheresis in rural and regional settings: a single-centre experience. Poster presentation at ASH 2023
11. **Joshi M** Obinutuzumab induced thrombocytopenia - an under recognised cause of immunotherapy related thrombocytopenia. ISTH 2023.
12. **Joshi M** Frequency and outcomes of obinutuzumab induced thrombocytopenia. ASH 2023.

New research projects 2023

Local Reference	Local Site Principal Investigator	Project Title	Study Phase/Type	ACT Health/CHS Area/Unit	Student Project (Y/N)	Sponsor Type
2023.STE.00013	Professor Dipti Talaulikar	The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed and refractory multiple myeloma in the era of novel therapy.	Low Risk	Haematology	No	Collaborative Group

2023.LRE.00067	Professor Dipti Talaulikar	Molecular and cellular analysis of the bone marrow environment in lymphoproliferative and myeloproliferative disorders	Low Risk	Haematology	No	Collaborative Group
2023.LRE.00072	Dr Phil Choi	Clinical Presentation and Outcomes of Warm Autoimmune Haemolytic Anaemia	Low Risk	Haematology	No	Investigator Led
2023.LRE.00091	Dr Pietro Di Ciaccio	Retrospective analyses of diagnosis, treatment and outcomes of lymphomas	Low Risk	Haematology	No	Investigator Led

Open clinical trials

Trial short reference	PI	Title	Disease	Sponsor Type
PNH Registry	Dr. Fathima Ayyalil	Paroxysmal Nocturnal Haemoglobinuria (PNH) Registry is a prospective multi-centre, multi-national, observational non-interventional study with enrolment of PNH patients treated with Soliris, and PNH patients not receiving Soliris therapy. The PNH Registry will capture post marketing pharmacovigilance	Paroxysmal Nocturnal Haemoglobinuria	Collaborative Group

		data on patients treated with Soliris and will collect information on the progression of disease for these patient groups		
GILEAD 5857 - Enhance 2	Dr. Samuel Bennett	A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia	Acute Myeloid Leukemia	Industry Sponsored
ALLG - NBCR	Dr. Maya Latimer	National Blood Cancer Registry		Collaborative
ALLG - AML M22	Dr. Samuel Bennett	ALLG AMLM22 The International AML Platform Consortium (IAPC) trial	Acute Myeloid Leukemia	Collaborative
PHARMA VAY736 1st line ITP	Dr. Phil Choi	VAYHIT1 – A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line	Immune Thrombocytopenia	Industry Sponsored

		corticosteroids in primary immune thrombocytopenia (CVAY736I12301)		
PHARMA VAY736 wAIHA	Dr. Phil Choi	VAYHIA – A phase III, randomized, double-blind study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment.	Warm autoimmune haemolytic anaemia	Industry Sponsored
VAY736 3	Dr. Phil Choi	A Phase 2 study to evaluate the efficacy and safety of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least a corticosteroid and a thrombopoietin receptor agonist (TPO-RA) (CVAQ12201)	Immune Thrombocytopenia	Industry Sponsored

Medical Oncology: Research Highlights 2023

Publications 2023

1. Aw YTV and Peters GD (2023) 'Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients', *Current Problems in Cancer: Case Reports*, 9:100209, doi:10.1016/j.cpcr.2022.100209.
2. Asklin, B., Hinds, A., Paterson, C. (2023). Exploring clinical decision-making among the uro-oncology MDT: A qualitative study. *Seminars in Oncology Nursing*. 11;151447. doi:10.1016/j.soncn.2023.151447.
3. Chan WY, Sim H-W, Abdi Haryono M, Yip D and Chin V (2023) 'Immune checkpoint inhibitors for advanced pancreatic cancer', *Cochrane Database of Systematic Reviews*, 2023(2), doi:10.1002/14651858.cd014523.
4. Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M and Nguyen A (2023) 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', *Therapeutic advances in medical oncology*, 15:17588359231156392–17588359231156392, doi:10.1177/17588359231156392.
5. Glyn T, Oar A, Vatandoust S, Heriot A and Jain A (2023) 'Rectal cancer treatment: an embarrassment of riches?', *ANZ Journal of Surgery*, 93(10):2293–2294, doi:10.1111/ans.18634.
6. Hao Y, Miraghazadeh B, Chand R, Davies AR, Cardinez C, Kwong K, Downes MB, Sweet RA, Cañete PF, D'Orsogna LJ, Fulcher DA, Choo S, Yip D, Peters G, Yip S, Witney MJ, Nekrasov M, Feng Z-P, Tscharke DC, Vinuesa CG and Cook MC (2023) 'CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4(+) T cells', *Cellular & molecular immunology*, 20(7):777–793, doi:10.1038/s41423-023-01027-8.
7. Hayes S, Obermair A, Mileshkin L, Davis A, Gordon LG, Eakin E, Janda M, Beesley VL, Barnes EH, Spence RR, Sandler C, Jones T, Vagenas D, Webb P, Andrews J, Brand A, Lee YC, Friedlander M, Pumpa K, O'Neill H, Williams M, Collaborative E, Stockler M and trial E (2023) 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial', *BMJ open*, 13(4):e067925–e067925, doi:10.1136/bmjopen-2022-067925.
8. Hu H-P, Archer C, Yip D and Peters G (2023) 'Clinical predictors of survival in real world practice in stage IV melanoma', *Cancer reports (Hoboken, N.J.)*, 6(2):e1691–e1691, doi:10.1002/cnr2.1691. Hu H-P, Archer C, Yip D and Peters G (2023) 'Clinical predictors of survival in real world practice in stage IV melanoma', *Cancer reports (Hoboken, N.J.)*, 6(2):e1691–e1691, doi:10.1002/cnr2.1691.
9. Jain A, Gormly KL, Glyn T, Sammour T, Koay EJ, Oar A, Jameson MB, Smyth EC and Vatandoust S (2023) 'Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022', *Asia-Pacific Journal of Clinical Oncology*, doi:10.1111/ajco.13974.
10. Kanjanapan Y, Guduguntla G, Varikara AK, Szajer J, Yip D, Cockburn J and Fadia M (2023) 'Author response for "Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune

Checkpoint Inhibitors in a Real-World Setting'',
doi:10.1177/15330338231209129/v3/response1.

11. Loft M, Lok SW, De Boer R, **Malik L**, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P and Gately L (2023) 'Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer', *Breast Cancer Research and Treatment*, 198(1):67–74, doi:10.1007/s10549-022-06856-1.
12. Ng JY, Warwick L, **Craft P**, Austen L, Ashford B, Gorddard N, Ballinger ML, Thomas DM, Blombery P, Tucker K and Polizzotto MN (2023) 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', *British Journal of Haematology*, 203(3):481–484, doi:10.1111/bjh.19059.
13. **O'Dea, A.**, Caulfield, R., & Roche, M. A. (2023). Impact of the practice environment on oncology and haematology nurses: a scoping review. *Cancer Nursing*, 00, <https://doi.org/10.1097/NCC.0000000000001264>
14. Paterson C, Roberts C, Li J, **Chapman M**, Strickland K, **Johnston N**, Law E, Bacon R, Turner M, Mohanty I, **Pranavan G** and Toohey K (2023) 'What are the experiences of supportive care in people affected by brain cancer and their informal caregivers: A qualitative systematic review', *Journal of cancer survivorship : research and practice* 1–22, doi:10.1007/s11764-023-01401-5.
15. **Shelley, D.**, Bail., K, Davis, D., Paterson, C. (2023). Oncology nurses' experiences of using health information systems (HIS) in the delivery of cancer care in a range of care settings: A Systematic Integrative Review. *Seminars in Oncology Nursing*.
16. Simon Davis DA, Ritchie M, Hammill D, Garrett J, Slater RO, Otoo N, Orlov A, Gosling K, Price J, **Yip D**, Jung K, Syed FM, Atmosukarto II and Quah BJC (2023) 'Identifying cancer-associated leukocyte profiles using high-resolution flow cytometry screening and machine learning', *Frontiers in immunology*, 14:1211064, doi:10.3389/fimmu.2023.1211064.
17. Soon JA, To YH, Alexander M, Trapani K, Ascierto PA, Athan S, Brown MP, Burge M, Haydon A, Hughes B, Itchins M, John T, Kao S, Koopman M, Li BT, Long G V, Loree JM, Markman B, Meniawy TM, Menzies AM, Nott L, Pavlakis N, Petrella TM, Popat S, Tie J, Xu W, **Yip D**, Zalcborg J, Solomon BJ, Gibbs P, McArthur GA, Franchini F and IJzerman M (2023) 'A tailored approach to horizon scanning for cancer medicines', *Journal of Cancer Policy*, 38:100441, doi:10.1016/j.jcpo.2023.100441.
18. Strickland, K., Pike, A., Toohey, K., **Craft, P.**, Acevska , J., Branniff, A., Paterson, C. (2023). "Lower drug costs, fewer side effects, and longer lives". Giving voice to women with stage IV breast cancer: lived experiences of unmet needs expressed on online platforms. *Journal of Clinical Nursing*.
19. **Yip D**, Soma A, **Pati N**, Spencer W, Hua B and Jagilly R (2023) 'Building Capability and Capacity: The Establishment of an Oncology Unit in the Solomon Islands', *JCO global oncology*, 9:e2200325–e2200325, doi:10.1200/GO.22.00325.

Conference oral presentations 2023

1. **Kanjanapan Y**, Anderson W, Smith M, Green J, Chalker E, **Craft P**. Real world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors. Clinical Oncology Society of Australia Annual Scientific Meeting 2023. 13-15 Nov 2023. Gold Coast.

Conference poster presentation 2023

1. Thavaneswaran S, Mersiades Po-Yen Lin F, Espinoza D, P. Grady J, Lee CK, Desa Ji, Brown MP, Grimison PS, O'Byrne KJ, Harrup RA, Nagrial A, Lucille Sebastian, Sarah Chinchen, Maya Kansara, **Paul Stanley Craft**, Michael Millward, John Simes, Anthony M. Joshua, David Morgan Thomas. Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy. Abstract 3127, 2023 ASCO Annual Meeting. 2- 6 June 2023. Chicago.
2. Frank Po-Yen Lin, Subotheni Thavaneswaran, Christine E Napier, John P. Grady, Maya Kansara, Lucille Sebastian, Damien Kee, Milita Zaheed, Michael Millward, Michael Paul Brown, Michail Charakidis, **Paul Stanley Craft**, Peter S. Grimison, Rosemary A. Harrup, Kenneth John O'Byrne, Jayesh Desai, Chee Khoon Lee, Mandy L. Ballinger, John Simes, David Morgan Thomas (2023). Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program. Abstract 1540, 2023 ASCO Annual Meeting. 2- 6 June 2023. Chicago.
3. Yeh Chen Lee, Damien Kee, Frank Po-Yen Lin, Subotheni Thavaneswaran, Christine E Napier, Michael Friedlander, Maya Kansara, Clare Scott, Peter S Grimison, Michelle Harrison, Bo Gao, **Alison Davis**, Philip Beale, Diana Adams, Anne Hamilton, Jayesh Desai, Chee Khoon Lee, Mandy L Ballinger, John Simes, David Morgan Thomas. Genomic Profiling of Gynaecological Sarcomas: Report from the Australia-wide Precision Oncology Program. CTOS 1-4 Nov 2023. Dublin, Ireland.
4. Kristina Lindemann, Heidi Liland, Mia Sejer Donner, Sue Brew, Yeh Chen Lee, Ingvild Vistad, Elisabeth Berge Nilsen, Janine Margaret Lombard, Mansoor Raza Mirza, Kristine Madsen, Anne Marie Hansson, John Andrews, Rachel Campbell, **Alison J. Davis**. GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology: Patients Expectations and Assessment of CarE. 2023 ASCO Annual Meeting. 2- 6 June 2023. Chicago.
5. Florence Joly, Isabelle Laure Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, **Alison J. Davis**, Emma Hudson, Domenica Lorusso, Germana Tognon, Ursula Hasler-Strub, Chel Hun Choi, Mehmet Ali Vardar, Stephanie Lheureux, Toon Van Gorp, David Shao Peng Tan, Fabian Trillsch, Lauriane Eberst, Céline Lescure, Anne-Claire Hardy-Bessard, Marie Chaix. Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGOT-en13 study). 2023 ASCO Annual Meeting. 2- 6 June 2023. Chicago
6. Damien Kee, Frank Po-Yen Lin, Subotheni Thavaneswaran, Christine E Napier, Michelle L. Harrison, Philip James Beale, Jodi Lynch, **Alison J. Davis**, Sumitra Ananda, Janine Margaret Lombard, Michael Friedlander, Maya Kansara, Lucille Sebastian, Chee Khoon Lee, Mandy L. Ballinger, John Simes, David Morgan Thomas. Molecular tumor profiling and therapy selection in advanced gynecological cancers: a retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program. 2023 ASCO Annual Meeting. 2- 6 June 2023. Chicago.

Research grants 2023

Project Title:	TIME: The Time toxicity involved in Medical treatment for platinum resistant or refractory ovarian cancer
Investigators:	Alison Davis
Funding Body:	ANZGOG Fund for New Research
Duration:	3 Years, Amount \$50000

Research HDR students, fellowships, research-related positions 2023

- Delilah Shelley. Impact of the digital health record on cancer care. Competitive PhD Scholarship (\$100,000).

New research projects 2023

Newly approved Clinical Trials

Local Reference	Local Site Principal Investigator	Project Title	Study Phase/Type	ACT Health/CHS Area/Unit	Sponsor Type
2023.STE.00104	Dr Ganes Pranavan	A Phase I/II Study of EPI-7386 in Combination with Enzalutamide compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer	Phase I Drug	Medical Oncology	Collaborative Group

Open clinical trials

Trial reference	PI	Title	Disease	Sponsor Type
ARTISTRY-7	Dr Alison Davis	Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer	Plat Res Ca Ovary -	Commercial
MoST	Dr Paul Craft	Molecular screening and therapeutics clinical trials	Rare Cancers – Molecular screening	Collaborative Group
MoST 8	Dr Paul Craft	Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations.	Advanced cancers harbouring HER2 amplifications or mutations.	Collaborative Group
KeyVibe006	Dr Geoffrey Peters	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)	Untreated, Unresectable, Stage III NSCLC	Commercial

FINER	Dr Yada Kanjanapan	A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor	Metastatic HER-2 Negative & ER+ Breast cancer, progressed on 1 st line CDK 4/6 Inhibitor & Aromatase Inhibitor	Collaborative Group
Finding my way	Dr Desmond Yip	Finding My Way: A randomised controlled trial evaluating an internet self-help program for cancer-related distress	Web-based psychosocial intervention for metastatic breast cancer	Collaborative Group
Aspire Panbela CL-SBP-101-04	Dr Ankit Jain	A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	phase III trial for untreated metastatic pancreatic ductal adenocarcinoma	Commercial
PEACE	Dr Alison Davis	Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)	Palliation in gynaec-oncology: evaluative and assessment of satisfaction with care.	Collaborative Group

Radiation Oncology: Research Highlights 2023

Publications 2023

1. Koh E, Barry N, Ebert MA, Moore A, Francis RJ, Ng SP, Back M, Chua B, Pinkham M, Pullar A, PullarPhillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, **Syed F**, Jung K, Chang J, Bece A, Clark C, Wada M and Scott AM (2023) 'PD-0648 FET-PET incorporation for GBM radiotherapy planning: multi-site FIG Study credentialling programme', *Radiotherapy and Oncology*, 182:S539–S540, doi:10.1016/s0167-8140(23)08942-9.
2. Ng JY, Warwick L, Craft P, **Austen L**, Ashford B, Gorddard N, Ballinger ML, Thomas DM, Blombery P, Tucker K and Polizzotto MN (2023) 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious *FANCM* variants: A case report and review of the literature', *British Journal of Haematology*, 203(3):481–484, doi:10.1111/bjh.19059.
3. Simon Davis DA, Ritchie M, Hammill D, Garrett J, Slater RO, Otoo N, Orlov A, Gosling K, Price J, Yip D, **Jung K**, **Syed FM**, Atmosukarto II and Quah BJC (2023) 'Identifying cancer-associated leukocyte profiles using high-resolution flow cytometry screening and machine learning', *Frontiers in immunology*, 14:1211064, doi:10.3389/fimmu.2023.1211064.
4. Siva S, Sakanun P, Mai T, Wong W, Lim A, Ludbrook J, Bettington C, **Rezo A**, Pryor D, Hardcastle N, Kron T, Higgs B, Le H, Skala M, Gill S, Eade T, Awad R, Sasso G, Vinod S, Montgomery R, Ball D and Bressel M (2023) 'Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases', *Journal of Clinical Oncology*, 41(19):3493–3498, doi:10.1200/jco.23.00150.

Conference presentations 2023

1. Martin Seng. (R) evolution – Canberra's Journey From 2018 to Beyond – Varian Australasian Oncology Summit 2023, Gold Coast

Conference posters 2023

1. Helen Troung. A Stereotactic Radiosurgery Service Transformed– ASMIRT 2023 Conference, Sydney

Research HDR students, fellowships, research-related positions 2023

Irradiation Immunity Interaction (I-Cube) Laboratory (Collaboration between ANU John Curtin School of Medical Research) Higher Degree Students

- Dillon Hammill (PhD), ANU, John Curtin School of Medical Research, I-CUBE Lab
- Jessica Garrett (PhD), ANU, John Curtin School of Medical Research, I-CUBE Lab

New research projects 2023

Local Reference	Local Site Principal Investigator	Project Title	Study Phase/Type	ACT Health/CHS Area/Unit	Student Project (Y/N)	Sponsor Type
2023.STE.00002	Dr Brandon Nguyen	NINJA - Novel Integration of New prostate radiation therapy schedules with adjuvant Androgen deprivation (TROG18.01)	Clinical Trial Other	Radiation Oncology	No	Commercial
2023.LRE.00005	Ms Helen Truong	Effect of Body Weight Changes on Thecal Sac Dose in Spine SBRT	Low Risk	Radiation Oncology	No	Investigator Led
2023.LRE.00057	Ms Charlene Zheng (Dr Amy Shorthouse)	A quality indicator project on rectal cancer radiation therapy at the TCH	Low Risk	Radiation Oncology	Yes - Masters	Investigator Led
2023.LRE.00230	Dr Amy Shorthouse	Retrospective review of radiotherapy in pancreatic cancer at The Canberra Hospital	Low Risk	Radiation Oncology	Yes - Bachelors	Investigator Led

Open clinical trials

Trial reference	PI	Title	Disease	Sponsor Type
2023.STE.00002	Dr Brandon Nguyen	NINJA - Novel integration of new prostate radiation therapy schedules with adjuvant androgen deprivation.	Prostate Cancer	Collaborative trial
2020.STE.00127	Dr Farhan Syed	FIG -Prospective, multicenter trial evaluating FET-PET in Glioblastoma.	Glioblastoma	Collaborative Group
ETH.2.18.033E	Dr Trish Pulvirenti	EXPERT– A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery	Breast Cancer	Collaborative Group

		and endocrine therapy in patients with molecularly characterised luminal A early breast cancer		
--	--	------------------------------------------------------------------------------------------------	--	--

Follow up clinical trials

Trial reference	PI	Title	Disease	Sponsor Type
ETH.4.12.075	Dr Lisa Sullivan	STARS - A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.	Breast Cancer	Collaborative Group
2020.STE.00192	Drs Paul Craft and Amy Shorthouse	IBIS -Implementation of a nurse-enabled, shared-care follow-up model for early breast cancer survivors.	Breast Cancer	Collaborative Group
ETH.9.13.230	Dr Angela Rezo	Aviator - Audio-Visual Investigation Advancing Thoracic Radiotherapy.	Thoracic Radiotherapy	Collaborative Group
ETH.4.17.071E	Dr Lisa Sullivan	Local Hero - A Phase II study of local therapy only (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive Breast Cancer.	Breast Cancer	Collaborative Group
ETH.9.14.240	Dr Andrew Lee	HPV-OPSCC - A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis	HPV Associated Oropharyngeal	Collaborative Group

		Locoregionally Advanced HPV-Associated Oropharyngeal.		
2022.STE.00052	Drs Angela Rezo and Jothy Selvaraj	AusCAT Database: Improving personalised decision making for oncology patients using data mining and rapid learning techniques.	AusCAT Database	
2022.STE.00169	Drs Angela Rezo, Kendell Shields Downton, Yaw Chin	Implementation of Mid- Ventilation Stereotactic Ablative Body Radiotherapy (SABR) for Stage I Non-Small Cell Lung Carcinoma (NSCLC)	Non-Small Cell Lung Carcinoma (NSCLC)	
2023.STE.00057	Drs Amy Shorthouse and Charlene Zheng	Quality indicators for Rectal Cancer Treatment at The Canberra Hospital	Rectal Cancer	Investigator led
2021.LRE.00073	Drs David Newsome, Farhan Syed, Chaturica Athukorala, Rebecca Webb- Myers	Radionecrosis following Stereotactic Radiotherapy to Brain Metastasis: Retrospective review of patients treated at Canberra Hospital	Brain Metastasis	Investigator led
2022.LRE.00001	Dr Amy Shorthouse, Darren Nguyen	Management of oesophageal cancer at The Canberra Hospital- a 10-year retrospective audit	Oesophaegeal Cancer	Investigator led
2021.LRE.00128	Kyle Jung, Martin Seng, Helen Gustafsson, Angeal Rezo, and Lisa Sullivan	Assessing the utility of hybrid volumetric modulated arc therapy on radiotherapy planning for breast cancer- (Part A) whole breast radiotherapy with tumour bed boost (Part B) whole breast/chest	Breast Cancer	

		wall radiotherapy with regional nodal irradiation.		
2023/ETH00382	Rachel Poldy, Brittany Smith, Conner Hayes, Libby Werner, Wesley Thom, TJ Chahal, Martin Seng, Helen Gustafsson, Jonathon Lee, and Jothy Selvaraj	AI-Rad Companion (AIRC) contouring assessment	AI-Rad Companion (AIRC) contouring assessment	

End of Life and Palliative Care: Research Highlights 2023

Publications 2023

1. Brennan F, **Chapman M**, Gardiner MD, Narasimhan M and Cohen J (2023) 'Our dementia challenge: arise palliative care', *Internal Medicine Journal*, 53(2):186–193, doi:10.1111/imj.16011.
2. **Chapman M** and Komesaroff P (2023) 'Radicalizing Hope', *Journal of Bioethical Inquiry*, doi:10.1007/s11673-023-10291-2.
3. **Chapman M**, Philip J and Komesaroff P (2023) 'Systems of Care and Experience for Dying Well', *Toward an Integrated Science of Wellbeing*284-C12P82, doi:10.1093/oso/9780197567579.003.0013.
4. Collier A and **Chapman M** (2023) 'Matters of care and the good death – rhetoric or reality?', *Current Opinion in Supportive & Palliative Care*, 17(3):208–213, doi:10.1097/spc.0000000000000663.
5. Emmerich N and **Chapman M** (2023) 'Suffering, existential distress and temporality in the provision of terminal sedation', *Journal of Medical Ethics*, 49(4):263–264, doi:10.1136/jme-2023-109018.
6. **Paterson C**, Roberts C, Li J, **Chapman M**, Strickland K, Johnston N, Law E, Bacon R, Turner M, Mohanty I, Pranavan G and Toohey K (2023) 'What are the experiences of supportive care in people affected by brain cancer and their informal caregivers: A qualitative systematic review', *Journal of cancer survivorship : research and practice*1–22, doi:10.1007/s11764-023-01401-5.
7. Toohey K, **Chapman M**, Rushby A-M, Urban K, Ingham G and Singh B (2023) 'The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic

- review with meta-analysis', *Journal of Cancer Survivorship*, 17(2):399–415, doi:10.1007/s11764-021-01153-0.
8. Yu Y, Hunter SC, Xiao L, Meyer C, Chapman M, Tan KP, Chen L, McKechnie S, Ratcliffe J, Ullah S, Kitson A, Andrade AQ and Whitehead C (2023) 'Exploring the role of a facilitator in supporting family carers when embedding the Support for Dementia programme in care services: A qualitative study', *Journal of Clinical Nursing*, 32(19–20):7358–7371, doi:10.1111/jocn.16836.

Research grants 2023

Project title: Dying, death literacy and Voluntary Assisted Dying – Educating community responses to assisted dying in the ACT

Funding body: ACT government Research Innovation Fund (RIF) Fellowship

CRCC Investigators: Michael Chapman

Amount: \$200k

Project title: Aboriginal and Torres Strait Islander End of Life Care Pathways

Funding body: Canberra Health Services Allied Health Research Support Grant

CRCC Investigators: Toni Ashmore, Michael Chapman

Amount: \$3990K

Research HDR students, fellowships, research-related positions 2023

- Toni Ashmore PhD candidate ANU, John Curtin School of Medicine
- Nikki Johnston PhD candidate UC, School of Nursing and Midwifery

New, ongoing and follow up research projects 2023

Local Reference	Local Site Principal CRCC Investigator	Project Title	Study Phase/Type	ACT Health/CHS Area/Unit	Student Project (Y/N)	Sponsor Type
2023.LRE.00216	Dr Michael Chapman	Clinician Education for Decision-Support for	Low Risk	Palliative Care	No	Investigator Led

		People with Dementia				
2020.ETH.00145	Kate Reed and Dr Chapman	Palliative–Strengthening the delivery of palliative care in an Australian Hospital through nursing leadership: a mixed methods action research study.	This was a full recruiting study, not a low risk study	Palliative Care	No	Collaborative Group
2022.ETH.00147	Toni Ashmore	End of Life Care in Acute Hospital Settings	High Risk	End of Life Care	Yes	Investigator Led
2018.LRE.00228	Toni Ashmore	End of Life File Audit	Low Risk	End of Life Care	Yes	Investigator Led
2021.ETH.00013	Toni Ashmore	Aboriginal and Torres Strait Islander End of Life Care Pathways Phase 2	High Risk	End of Life Care	No	Investigator Led

Acknowledgement of Country

 Canberra Health Services acknowledges the Ngunnawal people as traditional custodians of the ACT and recognises any other people or families with connection to the lands of the ACT and region. We acknowledge and respect their continuing culture and contribution to the life of this region.

© Australian Capital Territory, Canberra xxxxxxxx 20xx



Accessibility

Call (02) 5124 0000



Call 131 450

canberrahealthservices.act.gov.au/accessibility

